Journal of Men's Health · Published 2025-01-01 · DOI 10.22514/jomh.2025.030
Background: This study aimed to evaluate the efficacy and safety of Yiqi Yangxue Jiedu Decoction & Entecavir in male patients with decompensated hepatitis B cirrhosis. Methods: A retrospective analysis was conducted using clinical data from 195 male patients with decompensated hepatitis B cirrhosis treated at our hospital between February 2022 and February 2024. Based on treatment regimens, the patients were divided into the observation group (100 cases), treated with Yiqi Yangxue Jiedu Decoction and Entecavir, the control group (95 cases), treated with Entecavir. Both groups received standard Western medicine treatment. The clinical efficacy and safety of the treatments were compared. Results: The total effective rate in the observation group was significantly higher (p < 0.05). Among the observation group, patients with moderate liver cirrhosis exhibited a significantly higher total effective rate than those with severe liver cirrhosis, patients with low viral load demonstrated a significantly higher total effective rate than high viral load (p < 0.05). Post-treatment, the observation group showed significantly reduced alanine aminotransferase (ALT), total bilirubin (TBIL) levels and increased albumin (ALB) levels than the control group (p < 0.05). The observation group had significantly lower levels of type III procollagen (PC III), type IV collagen (IV-C), laminin (LN) and hyaluronic acid (HA) (p < 0.05), shorter prothrombin time (PT), higher prothrombin activity (PTA) post-treatment than control group (p < 0.05), while the incidence of adverse reactions was comparable of two groups (p < 0.05). After six months of follow-up, the observation group exhibited a significantly lower incidence of delayed adverse events (p < 0.05). Conclusions: The combination of Yiqi Yangxue Jiedu Decoction and Entecavir significantly improves treatment efficacy, enhances liver function recovery, reduces liver fibrosis in male patients with decompensated hepatitis B cirrhosis. The regimen also demonstrated good safety, supporting its potential for broader clinical application.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →